Instead of taking the traditional approach of replacing what s missing, the idea of fitusiran is to short circuit the body s anticoagulation system by targeting antithrombin.
The progress of gene therapies continues to be stymied by safety risks associated with the viruses used to deliver them. Takeda Pharmaceutical is partnering with Poseida Therapeutics in a bet that the biotech’s non-viral technologies could offer a safer alternative.